Provided by Tiger Trade Technology Pte. Ltd.

Weight Loss Drugs

1,561.28
-8.4900-0.54%
Number of Gainers:- -
Number of Losers:7
Number of Flat:- -
PE:- -
High:1,579.75
Open:1,579.75
Low:1,559.99
Close:1,569.77
Volume:45.89M
Turnover:4.76B
Market Cap:1.63T
Float Cap:1.56T

Loading ...

AlzeCure Pharma to Present at Aktiedagen Event in Stockholm

Reuters
·
Sep 08

Novo Nordisk (0QIU) Receives a Hold from Barclays

TIPRANKS
·
Sep 08

Novo Nordisk halts two trials testing ziltivekimab, Bloomberg reports

TIPRANKS
·
Sep 08

Yen advances to six-month high, chip stocks rise

Nicholas Reynolds / Bloomberg
·
Sep 08

Novo Nordisk announces STEP Young phase 3 trial met its primary endpoint

TIPRANKS
·
Sep 08

Novo Nordisk (NVO) Hit by Another Heart Drug Setback

TIPRANKS
·
Sep 08

Novo Nordisk A/S Series B Stock Flat Monday, Underperforms Market

Dow Jones
·
Sep 08

Novo Nordisk Stock (NVO) Falls Despite Success in Children’s Weight-Loss Trial

TIPRANKS
·
Sep 07

The Second Act of Biotech

TIPRANKS
·
Sep 07

ASB Ventures-Backed Boundary Zhikong’s Navista eVTOL Navigation System Enters CAAC Airworthiness Review

Reuters
·
Sep 07

Sino Biopharmaceutical Stock Slides 1.2% in Hong Kong, Underperforms Competitors

Dow Jones
·
Sep 07

Novartis India to Acquire 'Minipress' Trademarks from Pfizer

Reuters
·
Sep 07

Second Clinical Trial Blow in a Week for Novartis as Heart Drug Disappoints, Dragging Down Amgen Shares

Stock News
·
Sep 07

Clever Culture Systems Wins Expanded Novo Nordisk Order as APAS Nears Global Validation

TIPRANKS
·
Sep 07

A Novartis Heart Drug Trial Stumbles. Can a Rare-Disease Treatment Lift Shares?

Dow Jones
·
Sep 06

Pfizer Ramps Up Obesity And Eczema Bets, Investors Watch

TIPRANKS
·
Sep 05

Amgen EVP, CFO Thomas J.W. Dittrich Files Initial Beneficial Ownership Statement

Reuters
·
Sep 05

Pfizer Inc. Stock Underperforms Friday When Compared to Competitors

Dow Jones
·
Sep 05

Healthcare Stocks Pick up Steam as Investors Play Offense and Defense

Dow Jones
·
Sep 05

Pfizer’s Next Move in Obesity Drugs: What the New VESPER-JM Trial Means for PFE Investors

TIPRANKS
·
Sep 05